“An Unrelenting Disaster Zone”: Merck’s Alzheimer’s Drug Fails in Phase III Post author:Sam Post published:February 13, 2018 Post category:BioPharma Alzheimer’s drug development took another hit. Source: BioSpace You Might Also Like QIAGEN N.V. Joins CANCER-ID Consortium For Liquid Biopsy Workflows March 30, 2017 Lexicon Pharma Secures Up to $200M Non-Dilutive Term Loan Financing December 4, 2017 Takeda Axes Sales Jobs, Forces Hundreds of Employees to Relocate to Boston July 17, 2017
